Search

Displaying results 1101 - 1110 of 7283 in total
  1. Drug

    Piperaquine

    go.drugbank.com/drugs/DB13941
    ApprovedInvestigational

    It has come back into use in combination with the artemisinin derivative [DB11638] as part of the combination product Eurartesim [FDA Label]. … Eurartesim was first authorized for market by the European Medicines Agency in October 2011.

    Mixtures: D-ARTEPP, D-ARTEPP DISPERSIBLE
  2. Drug

    Sarecycline

    go.drugbank.com/drugs/DB12035
    ApprovedInvestigational

    Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because … Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007

  3. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC. … [L44361,L44366] Adagrasib joins [sotorasib] as another KRAS<sup>G12C</sup> inhibitor approved by the FDA.[A254062]

    Synonyms: ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-
  4. Drug

    Potassium acetate

    go.drugbank.com/drugs/DB14498
    Approved

    Mixtures: ELETTROLITICA DI MANTENIMENTO CON GLUCOSIO FKI, ELETTROLITICA DI MANTENIMENTO CON GLUCOSIO FKI
  5. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … Menin is a scaffold protein that interacts with both the wild-type and rearranged KMT2A, which is crucial for KMT2A activity and the maintenance of _HOXA_ expression and leukemogenesis.

  6. Drug

    Sucralfate

    go.drugbank.com/drugs/DB00364
    ApprovedInvestigational

    Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis … It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076].

    Categories: Aluminum ComplexSynonyms: Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
  7. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    approved by certain organizations like the European Medicines Agency [L2079]. … Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line.

  8. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    ], which are derivatives of [vitamin A]. … [L39990,L40020] It has been granted rare pediatric disease and breakthrough therapy designations from the US FDA, although a previously submitted NDA was withdrawn in August 2021 pending the resubmission

  9. Drug

    Netupitant

    go.drugbank.com/drugs/DB09048
    ApprovedInvestigational

    Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo. … Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy

  10. Drug

    Vestronidase alfa

    go.drugbank.com/drugs/DB12366
    ApprovedInvestigational

    Vestronidase alfa, or vestronidase alfa-vjbk, is a recombinant human lysosomal beta glucuronidase that is a purified enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. … Some affected individuals do not survive infancy, while others may live into adolescence or adulthood and patients may experience developmental delay and progressive intellectual disability [FDA Label]